Skip to main content
AYTU BIOPHARMA, INC logo

AYTU BIOPHARMA, INC — Investor Relations & Filings

Ticker · AYTU ISIN · US0547548745 US Manufacturing
Open in API
Filings indexed 890 across all filing types
Latest filing 2024-11-09 Director's Dealing
Country US United States of America
Listing US AYTU

About AYTU BIOPHARMA, INC

https://aytubio.com/

Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing novel therapeutics. The company concentrates on advancing innovative medicines for complex central nervous system (CNS) diseases, with a particular emphasis on treatments for Attention-Deficit/Hyperactivity Disorder (ADHD) and Major Depressive Disorder (MDD). Its business model involves identifying, acquiring, and commercializing new products to improve the quality of life for patients with unmet medical needs.

Recent filings

Filing Released Lang Actions
Director's Dealing 2024
Director's Dealing
2024-11-09 English
Director's Dealing 2024
Director's Dealing
2024-11-09 English
Regulatory Filings 2024
Regulatory Filings
2024-10-16 English
FORM S-3/A
Regulatory Filings Classification · 100% confidence The document is a Form S-3/A, which is a registration statement amendment filed with the SEC under the Securities Act of 1933. It is a pre-effective amendment to a registration statement for securities issuance, including exhibits and indemnification provisions. The document is not a financial report, earnings release, or management discussion, but rather a regulatory filing related to securities registration and offering. It does not contain financial statements or earnings data but focuses on legal and procedural information for securities issuance. Therefore, it fits the category of Regulatory Filings (RNS).
2024-10-11 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a correspondence letter addressed to the SEC regarding a Registration Statement on Form S-3. It requests acceleration of the effective date of the Registration Statement. The content is a formal communication related to a capital raising filing but does not contain financial data or the actual registration statement itself. The document length is short (1312 characters), and it is clearly a regulatory communication rather than a report or announcement of results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such correspondence and regulatory communications.
2024-10-07 English
Regulatory Filings 2024
Regulatory Filings
2024-10-03 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.